Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2953-2956

  Safranek, J ^a   Holubec Jr , Lubos ^a,b,c   Topolcan, O ^b   Pesta, M ^b   Klecka, J ^a   Vodicka, J ^a   Finek, J ^a   Kormunda, S ^b   Pesek, M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NONE   (Czech Republic)

Author keywords

Expression of mRNA; MMP 7; NSCLC; Real time PCR; TIMP 1

Indexed keywords

MATRILYSIN; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMOID TUMOR; GENE EXPRESSION; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE GENE; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34547788854     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Choy H, Pass HI, Rossel R and Traynor A: Evidence-based approach to oncology. In: Oncology: An Evidence-based Approach. Chang AE. 1st ed., New York, Springer, pp. 545-621, 2006.
2. Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheld HH, Broermann P, Berdel WE, Macha HN and Thomas M: Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer Lung Cancer 36(3): 265-270, 2002.
3. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J and Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25(5): 3387-3392, 2005.
4. Turpeenniemi-Hujanen T: Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87(3-4): 287-297, 2005.
5. Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y and Fujii Y: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 101(2): 242-247, 2001.
6. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K and Kosma VM: Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer Relation to clinico-pathological factors, beta-catenin and prognosis. Lung Cancer 16: 14-19, 2006.
7. Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, Nakatani Y, Kimura S, Kitajima H, Koshikawa N, Miyazaki K and Kitamura H: Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 28(5): 613-622, 1997.
8. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S and Kawai T: Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 35(3): 249-255, 2002.
9. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W and Hossfeld DK: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13(10): 1550-1557, 2002.
10. Jumper C, Cobos E and Lox C: Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 98(2): 173-177, 2004.
11. Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B and Pantel K: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103(5): 647-651, 2003.
12. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V and Turpeenniemi-Hujanen T: Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in Stage I-III lung carcinoma. Cancer Lett 236(1): 125-132, 2006.
13. Lin TS, Chiou SH, Wang LS, Huang HH, Chiang SF, Shih AY, Chen YL, Chen CY, Hsu CP, Hsu NY, Chou MC, Kuo SJ and Chow KC: Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 12(4): 717-723, 2004.